ANTAZOLINE HEMISULFATE

First approved in 1948

Details

Stereochemistry	ACHIRAL
Molecular Formula	2C17H19N3.H2O4S
Molecular Weight	628.784
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OS(O)(=O)=O.C(N(CC1=CC=CC=C1)C2=CC=CC=C2)C3=NCCN3.C(N(CC4=CC=CC=C4)C5=CC=CC=C5)C6=NCCN6

InChI

InChIKey=UKNPBFRSHRDSCJ-UHFFFAOYSA-N

InChI=1S/2C17H19N3.H2O4S/c2*1-3-7-15(8-4-1)13-20(14-17-18-11-12-19-17)16-9-5-2-6-10-16;1-5(2,3)4/h2*1-10H,11-14H2,(H,18,19);(H2,1,2,3,4)

HIDE SMILES / InChI

Molecular Formula	H2O4S
Molecular Weight	98.078
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C17H19N3
Molecular Weight	265.3529
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugbank.ca/drugs/DB08799
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68000865

Antazoline is an antagonist of histamine H1 receptors. It selectively bind to but does not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Antazoline in combination with naphazoline (VASOCON-A®) is indicated to relieve the symptoms of allergic conjunctivitis.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H1 receptor 315 Target ID: CHEMBL3943 Sources: https://www.drugbank.ca/drugs/DB08799	Antagonist 2778		38.4 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Allergic conjunctivitis 100 Sources: http://www.empr.com/vasocon-a/drug/1227/	Palliative		Approved 8429	VASOCON-A Approved Use Temporary relief of ocular redness and itching. Launch Date 1990

PubMed

Title	Date	PubMed
Interactions of ligands at angiotensin II-receptors and imidazoline receptors.	2001 Feb	11286399
Pharmacometric analysis of alpha1-adrenoceptor function in rat tail artery pretreated with lipopolysaccharides.	2001 Nov-Dec	11985334
Inhibition of voltage-gated Ca2+ channels by antazoline.	2002 Oct 7	12395109
Conjunctival allergen challenge: models in the investigation of ocular allergy.	2003 Jul	12791217
Evaluation of the phencyclidine-like discriminative stimulus effects of novel NMDA channel blockers in rats.	2003 Nov	12851738
Net analyte signal-based simultaneous determination of antazoline and naphazoline using wavelength region selection by experimental design-neural networks.	2006 Feb 15	18970453
A rapid derivative spectrophotometric method for simultaneous determination of naphazoline and antazoline in eye drops.	2006 Jan	16394564
Simultaneous determination of antazoline and naphazoline by the net analyte signal standard addition method and spectrophotometric technique.	2010 Nov-Dec	21313830
Treatment of allergic conjunctivitis: results of a 1-month, single-masked randomized study.	2010 Sep-Oct	20383847
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.	2011 Jul 14	21599003

Patents

Sample Use Guides

In Vivo Use Guide

1-2 drops up to 4 times daily.

Route of Administration: Other

In Vitro Use Guide

The antihistaminic agent, antazoline, was tested for its ability to compete for [3H]pyrilamine, [3H]tiotidine and [3H]N-methyl histamine binding to rodent brain H1, H2 and H3 histamine receptors, respectively. Antazoline exhibited the highest affinity for H1-receptors (dissociation constant, Ki = 38.4 +/- 4.4 nM), and was considerably weaker at H2- (K1 = 44,433 +/- 1,763 nM) and H3-receptors (Ki = 42,400 +/- 7,527 nM).

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:09:23 GMT 2023` Edited by `admin` on `Sat Dec 16 11:09:23 GMT 2023`
Record UNII	PHS9SV397D
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ANTAZOLINE HEMISULFATE

Common Name

English

1H-IMIDAZOLE-2-METHANAMINE, 4,5-DIHYDRO-N-PHENYL-N-(PHENYLMETHYL)-, SULFATE (2:1)

Systematic Name

English

Code System Code Type Description

CAS

84803-70-3

Created by admin on Sat Dec 16 11:09:23 GMT 2023 , Edited by admin on Sat Dec 16 11:09:23 GMT 2023

PRIMARY

EPA CompTox

DTXSID701005096

Created by admin on Sat Dec 16 11:09:23 GMT 2023 , Edited by admin on Sat Dec 16 11:09:23 GMT 2023

PRIMARY

FDA UNII

PHS9SV397D

Created by admin on Sat Dec 16 11:09:23 GMT 2023 , Edited by admin on Sat Dec 16 11:09:23 GMT 2023

PRIMARY

PUBCHEM

57354328

Created by admin on Sat Dec 16 11:09:23 GMT 2023 , Edited by admin on Sat Dec 16 11:09:23 GMT 2023

PRIMARY

Related Record Type Details


					DHA8014SS1

ANTAZOLINE

PARENT -> SALT/SOLVATE

Amount:

Related Record Type Details


					DHA8014SS1

ANTAZOLINE

ACTIVE MOIETY

Amount:

Details

SMILES

InChI

DescriptionSources: https://www.drugbank.ca/drugs/DB08799Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68000865

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.drugbank.ca/drugs/DB08799
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68000865